Review anchor
Suppressor of tumorigenicity 14 protein
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Suppressor of tumorigenicity 14 protein
CHEMBL3018
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Suppressor of tumorigenicity 14 protein as ChEMBL target CHEMBL3018, mapped to UniProt Q9Y5Y6. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3018
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9Y5Y6
Suppressor of tumorigenicity 14 protein
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Suppressor of tumorigenicity 14 protein matters
Suppressor of tumorigenicity 14 protein is reviewed as Suppressor of tumorigenicity 14 protein (UniProt Q9Y5Y6); the current evidence base includes 2 approved drugs, 557 compounds, and 93 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Suppressor of tumorigenicity 14 protein
Suppressor of tumorigenicity 14 protein Sequence length is 855 aa.
Review this target as Suppressor of tumorigenicity 14 protein, mapped to UniProt Q9Y5Y6. Sequence length is 855 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9Y5Y6
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 557 compounds, and 93 assays for this target. The dominant activity type is KI. CHEMBL3916317 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL3916317 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Suppressor of tumorigenicity 14 protein matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9Y5Y6, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
557
Total Compounds
93
Total Assays
2
Approved Drugs
IC50: 95.0, KI: 485.0, KD: 6.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3916317
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL2086421
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL273264
|
10.7 | Ki | Clinical |
|
|
No preferred name
CHEMBL3354674
|
10.2 | Ki | — |
|
|
No preferred name
CHEMBL3655686
|
10.2 | Ki | — |
Source Header